Travere Therapeutics SVP sells $335k in stock

On September 15, 2026, Sandra Calvin, Senior Vice President and Chief Accounting Officer of Travere Therapeutics Inc. (NASDAQ: TVTX), sold 5,375 shares of the company's common stock. The sale amounted to $335,004, with shares priced between $62.135 and $63.6633 per share, in accordance with a pre-approved Rule 10b5-1 trading plan.

The company's stock price has risen by 167% over the past year, currently trading at $64.74, close to its 52-week high of $68.73. InvestingPro analysts suggest the stock may be overvalued, with a fair value estimate of $58.24. During the same day, Calvin purchased 5,375 shares of Travere Therapeutics common stock by exercising employee stock options, spending $129,997.

With these transactions, she now directly owns 42,353 shares of the company. Additional employee stock options held by Calvin include 3,750 and 17,875 shares, with various vesting and expiration terms. Travere Therapeutics reported strong second-quarter revenue of $169.6 million, surpassing expectations, driven by the success of its kidney drug FILSPARI, which increased by 96% year-over-year to $141.1 million.

Despite a recent price target raise to $62 from $43 by Stifel, maintaining a Hold rating, FILSPARI has seen record demand, especially in the FSGS market and IgA nephropathy treatments.